Clinical trial
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von…
NCT00089765 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00089765 |
|---|---|
| Title | Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
| Official title | Pilot Study of Intravitreal Injection of Ranibizumab (rhuFAB V2) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Von Hippel-Lindau Syndrome |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 5 |
| Start date | Aug 10, 2004 |
| Completion | Aug 15, 2007 |
| First posted | Aug 13, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: